Personalized BPH/LUTS Treatment Systems via Synergistic Combinations of Mast Cell Inhibition and Advanced Technologies

The present inventive concept integrates mast cell inhibition with AI, IoT, blockchain, and nanotechnology to create personalized treatment systems for BPH/LUTS, enabling real-time monitoring, optimized treatment outcomes, and secure data management.

Benign prostatic hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS) are prevalent conditions affecting millions of men worldwide. The original patent disclosed combination therapies comprising mast cell inhibitors and histamine receptor antagonists, but lacked personalized treatment approaches and secure data management. The present inventive concept addresses these limitations by incorporating advanced technologies to create a more comprehensive and effective treatment system.

The inventive concept comprises a mast cell inhibitor, a histamine receptor antagonist, and a blockchain-based patient monitoring platform for personalized treatment optimization. The system utilizes machine learning algorithms trained on a dataset of patient responses to predict treatment outcomes and optimize dosages. Additionally, the system incorporates a wearable device for real-time symptom monitoring and an AI-powered analytics module for providing personalized treatment recommendations. The composition for treating BPH/LUTS includes a mast cell stabilizer, a histamine receptor antagonist, and nanoparticles for targeted delivery to the prostate gland.

The present inventive concept's novelty lies in the synergistic combination of mast cell inhibition with AI, IoT, blockchain, and nanotechnology, which enables personalized treatment approaches and secure data management. The inventive step is the integration of these distinct technologies to create a more comprehensive and effective treatment system for BPH/LUTS.

Alternative embodiments may include the use of different machine learning algorithms, varying types of nanoparticles for targeted delivery, or the incorporation of additional advanced technologies such as augmented reality for patient education and engagement. Variations may also include different wearable device designs or the use of alternative blockchain platforms for secure data management.

The present inventive concept has significant commercial potential in the pharmaceutical and medical device industries, with a target market including healthcare providers, researchers, and patients suffering from BPH/LUTS. The system's ability to provide personalized treatment approaches and secure data management addresses a significant unmet need in the market, offering a competitive advantage over existing treatment options.